Geron Corporation reported financial results for the quarter ended June 30, 2026, announcing RYTELO net product revenue of $57.5 million, an 11% increase from Q1 2026 and a 17% rise year-over-year. The company incurred a net loss of $16.7 million, or $0.02 per share, driven by non-cash inventory-related expenses that increased cost of goods sold to $9.2 million. Geron reiterated its full-year 2026 guidance, expecting RYTELO net product revenue between $220 million and $240 million and total operating expenses between $230 million and $240 million. The firm ended the quarter with approximately $327 million in cash and marketable securities. Additionally, Geron appointed Chinmaya Rath as Chief Business Officer to broaden its leadership team. Geron is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for blood cancers.